Novel Topical Esmolol Hydrochloride (Galnobax) for Diabetic Foot Wound: Phase 1/2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Parallel-Group Study

Overview of attention for article published in Advances in Wound Care, November 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#39 of 401)
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 3 news outlets

twitter: 1 X user

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 16 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

Beta-blocker gel shows promise for diabetic foot ulcers

Pediatric News , 23 May 2023

Twice-daily esmolol hydrochloride gel (Galnobax, NovaLead) appears to significantly improve closure of diabetic foot ulcers…

Beta Blocker Gel Shows Promise for Diabetic Foot Ulcers

Medscape, 23 May 2023

Twice-daily esmolol hydrochloride gel (Galnobax, NovaLead) appears to significantly improve closure of diabetic foot ulcers…

Indische Phase-III-Studie Betablocker-Gel bessert diabetische Fußulzera

Deutsche Apotheker Zeitung , 08 Dec 2022

Fußulzera bei Diabetikern heilen schwer ab und können derzeit nur konservativ versorgt werden.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.